Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Guardant Health Inc's Business Segments
Guardant Health Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 302
Regions Reported
1
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 302 | 100% |
Revenue Share by Region - Q1 FY2026
- Non-US5.6%
Revenue by Geographic Region - Q1 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Non-US | $ 17 | 5.6% |
Revenue by Product & Service Category - Q1 FY2026
- Oncology67.9%
- Biopharma & Data17.6%
- Screening13.8%
- Licensing & Other0.7%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Oncology | $ 205 | 67.9% |
| Biopharma & Data | $ 53 | 17.6% |
| Screening | $ 42 | 13.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Guardant Health Inc dataset.
Description of Guardant Health Inc
Guardant Health Inc. is a leading precision oncology company that aims to transform cancer care through comprehensive genomic sequencing solutions. The company is based in Redwood City, California, and was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz.
Guardant Health's core technology is called Guardant360, a non-invasive liquid biopsy test that uses genomic sequencing to analyze a patient's cancer. This test allows oncologists to identify mutations and alterations in a patient's cancer DNA, which can help guide treatment decisions. In addition, Guardant Health has developed a range of other liquid biopsy tests, including GuardantOMNI, GuardantINFORM, and GuardantHEALTHY, which can detect cancer early, monitor disease progression, and identify potential relapse.
Guardant Health has also developed proprietary bioinformatics algorithms and machine learning techniques to interpret the large amounts of genomic data generated by these tests. These algorithms are used to predict a patient's response to various treatment options and identify new targets for therapeutics.
Guardant Health has partnerships with several global pharmaceutical companies to develop companion diagnostic tests for their cancer therapies. In addition, the company has formed collaborations with leading cancer centers and research institutions to conduct clinical trials and advance the use of liquid biopsies in cancer care.
In 2018, Guardant Health went public on the NASDAQ stock exchange, and its shares are now listed under the symbol GH. The company has rapidly grown its revenue and customer base, and in 2020, it was named one of the fastest-growing companies in North America by Deloitte's Technology Fast 500.
Guardant Health's mission is to help improve outcomes for cancer patients through precision oncology. The company is dedicated to using the power of genomics and data science to revolutionize cancer care and ultimately, find a cure for this devastating disease.
Guardant Health's core technology is called Guardant360, a non-invasive liquid biopsy test that uses genomic sequencing to analyze a patient's cancer. This test allows oncologists to identify mutations and alterations in a patient's cancer DNA, which can help guide treatment decisions. In addition, Guardant Health has developed a range of other liquid biopsy tests, including GuardantOMNI, GuardantINFORM, and GuardantHEALTHY, which can detect cancer early, monitor disease progression, and identify potential relapse.
Guardant Health has also developed proprietary bioinformatics algorithms and machine learning techniques to interpret the large amounts of genomic data generated by these tests. These algorithms are used to predict a patient's response to various treatment options and identify new targets for therapeutics.
Guardant Health has partnerships with several global pharmaceutical companies to develop companion diagnostic tests for their cancer therapies. In addition, the company has formed collaborations with leading cancer centers and research institutions to conduct clinical trials and advance the use of liquid biopsies in cancer care.
In 2018, Guardant Health went public on the NASDAQ stock exchange, and its shares are now listed under the symbol GH. The company has rapidly grown its revenue and customer base, and in 2020, it was named one of the fastest-growing companies in North America by Deloitte's Technology Fast 500.
Guardant Health's mission is to help improve outcomes for cancer patients through precision oncology. The company is dedicated to using the power of genomics and data science to revolutionize cancer care and ultimately, find a cure for this devastating disease.
Guardant Health Inc. is a leading precision oncology company that specializes in non-invasive genomic diagnostics and companion diagnostics for cancer patients. Its innovations are centered on blood-based genomic testing, providing crucial insights into cancer biology and helping to inform targeted treatments.
Segments, Products, and Services
1. Guardant360
Guardant360 is Guardant Healths flagship product, recognized for being a comprehensive liquid biopsy test. This test is pivotal in the realm of precision oncology as it provides an expansive genomic profile of solid tumors through a simple blood sample.
- Key Features:
- Comprehensive Analysis: The Guardant360 test assesses more than 50 genes known to be associated with cancer, thereby identifying mutations that may influence the treatment pathway.
- Clinical Application: The information gleaned from this test enables healthcare providers to better match patients with targeted therapies, immunotherapies, and relevant clinical trials. This aligns treatment options more closely with the specific genetic alterations in a patient’s cancer.
- Reporting: Physicians receive detailed reports that highlight actionable insights and clinical significance of the identified mutations, which can significantly impact treatment decisions.
GuardantOmni
Building on the framework laid by Guardant360, GuardantOmni offers a broader range of genomic analysis capable of detecting alterations across various solid tumors.
- Key Features:
- Extensive Gene Coverage: This test covers over 500 genes, thereby providing a more extensive genomic profile by utilizing both circulating tumor DNA (ctDNA) and tumor DNA.
- Insight into Resistance Mechanisms: GuardantOmni is particularly useful in identifying potential resistance mechanisms in tumors, thus helping in the adaptation of treatment strategies based on the evolving landscape of the disease.
- Broader Tumor Applicability: This test is designed to be applicable across all solid tumor types, making it a versatile tool in clinical oncology.
LUNAR
LUNAR is Guardant Healths research-use-only product focused on the early detection of cancer, exemplifying the company’s commitment to innovation and early intervention.
- Key Features:
- Proprietary Technology: This liquid biopsy test employs advanced methodologies to detect ctDNA in the early stages of cancer, making it especially relevant for asymptomatic individuals.
- Goal of Early Detection: By allowing for the detection of cancer at an earlier stage, LUNAR aims to enhance patient outcomes through timely intervention, which is crucial for improving long-term survival rates.
Companion Diagnostics
In addition to their primary products, Guardant Health collaborates with pharmaceutical companies to create companion diagnostic tests. These tests are critical in identifying patients who are likely to benefit from specific therapies, thus facilitating personalized treatment approaches.
- Collaboration with Pharmaceuticals: The partnership with drug companies enables the development of tests that align with new therapeutic agents in the pipeline, thereby guiding optimal patient selection for clinical trials and treatment.
- Patient Stratification: Companion diagnostics play a vital role in stratifying patient populations to ensure that therapies are administered to those most likely to respond, which can enhance clinical outcomes and optimize resource utilization.
Summary
Guardant Health Inc. stands at the forefront of precision oncology with its innovative product suite that emphasizes non-invasive genomic diagnostics. Each segment—Guardant360, GuardantOmni, and LUNAR—serves a unique purpose, ranging from comprehensive tumor profiling to early detection of cancer. Coupled with companion diagnostics, Guardant Health provides essential tools that empower healthcare providers to make informed, data-guided treatment decisions, ultimately aimed at improving patient outcomes in the complex landscape of cancer treatment.
Segments, Products, and Services
1. Guardant360
Guardant360 is Guardant Healths flagship product, recognized for being a comprehensive liquid biopsy test. This test is pivotal in the realm of precision oncology as it provides an expansive genomic profile of solid tumors through a simple blood sample.
- Key Features:
- Comprehensive Analysis: The Guardant360 test assesses more than 50 genes known to be associated with cancer, thereby identifying mutations that may influence the treatment pathway.
- Clinical Application: The information gleaned from this test enables healthcare providers to better match patients with targeted therapies, immunotherapies, and relevant clinical trials. This aligns treatment options more closely with the specific genetic alterations in a patient’s cancer.
- Reporting: Physicians receive detailed reports that highlight actionable insights and clinical significance of the identified mutations, which can significantly impact treatment decisions.
GuardantOmni
Building on the framework laid by Guardant360, GuardantOmni offers a broader range of genomic analysis capable of detecting alterations across various solid tumors.
- Key Features:
- Extensive Gene Coverage: This test covers over 500 genes, thereby providing a more extensive genomic profile by utilizing both circulating tumor DNA (ctDNA) and tumor DNA.
- Insight into Resistance Mechanisms: GuardantOmni is particularly useful in identifying potential resistance mechanisms in tumors, thus helping in the adaptation of treatment strategies based on the evolving landscape of the disease.
- Broader Tumor Applicability: This test is designed to be applicable across all solid tumor types, making it a versatile tool in clinical oncology.
LUNAR
LUNAR is Guardant Healths research-use-only product focused on the early detection of cancer, exemplifying the company’s commitment to innovation and early intervention.
- Key Features:
- Proprietary Technology: This liquid biopsy test employs advanced methodologies to detect ctDNA in the early stages of cancer, making it especially relevant for asymptomatic individuals.
- Goal of Early Detection: By allowing for the detection of cancer at an earlier stage, LUNAR aims to enhance patient outcomes through timely intervention, which is crucial for improving long-term survival rates.
Companion Diagnostics
In addition to their primary products, Guardant Health collaborates with pharmaceutical companies to create companion diagnostic tests. These tests are critical in identifying patients who are likely to benefit from specific therapies, thus facilitating personalized treatment approaches.
- Collaboration with Pharmaceuticals: The partnership with drug companies enables the development of tests that align with new therapeutic agents in the pipeline, thereby guiding optimal patient selection for clinical trials and treatment.
- Patient Stratification: Companion diagnostics play a vital role in stratifying patient populations to ensure that therapies are administered to those most likely to respond, which can enhance clinical outcomes and optimize resource utilization.
Summary
Guardant Health Inc. stands at the forefront of precision oncology with its innovative product suite that emphasizes non-invasive genomic diagnostics. Each segment—Guardant360, GuardantOmni, and LUNAR—serves a unique purpose, ranging from comprehensive tumor profiling to early detection of cancer. Coupled with companion diagnostics, Guardant Health provides essential tools that empower healthcare providers to make informed, data-guided treatment decisions, ultimately aimed at improving patient outcomes in the complex landscape of cancer treatment.